o rly? Pharmacyclics Receives Refuse to File Letter for Xcytrin Conference Call at 9:00 AM Eastern Time SUNNYVALE, Calif., Feb 21, 2007 /PRNewswire-FirstCall via COMTEX/ -- Pharmacyclics, Inc. (PCYC) today announced that it has received a refuse to file letter from the U.S. Food and Drug Administration (FDA) for the company's new drug application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection for the treatment of non-small cell lung cancer patients with brain metastases. In the letter, the FDA stated that the company's application is not sufficiently complete to permit a substantive review based on clinical studies that failed to demonstrate statistically significant differences between treatment arms in the primary endpoints. "We will be evaluating our options with Xcytrin for the brain metastases indication and determine the best path forward," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. "Beyond this indication, the clinical development program with Xcytrin continues on multiple fronts. Several ongoing trials are evaluating Xcytrin in non-small cell lung cancer and other cancers. We are also moving forward with several other novel compounds, which are in clinical and preclinical development
Care to enlighten us a little about how you are screening these stocks(news,technicals, major movers, etc.). I noticed they are <$6.00.Is this a coincidence ? Or is this your focus?
it reached 3, and came back down. you should have sold this piece of shit by now. it is purely for day-trading, don't hold it overnight.